HPV Vaccine Driving Down Cervical Pre-Cancer Rates
Thursday, April 18, 2019
The human papillomavirus (HPV) vaccine is largely responsible for a decline in precancerous cervical lesions among young women in the United States, a new government report shows.
The number of these precancerous lesions detected during screening went down from an estimated 216,000 cases in 2008 to 196,000 cases in 2016, researchers from the U.S. Centers for Disease Control and Prevention found.
Controversial HPV Vaccine Shown to be Highly Effective in Wiping Out Cervical Cancer
Sunday, March 31, 2019
CDC recommends only two HPV shots for younger adolescents
Tuesday, October 25, 2016
CDC today recommended that 11- to 12-year-olds receive two doses of HPV vaccine at least six months apart rather than the previously recommended three doses to protect against cancers caused by human papillomavirus (HPV) infections. Teens and young adults who start the series later, at ages 15 through 26 years, will continue to need three doses of HPV vaccine to protect against cancer-causing HPV infection.
HPV Sharply Reduced in Teenage Girls Following Vaccine, Study Says
Tuesday, February 23, 2016
A vaccine introduced a decade ago to combat the sexually transmitted virus that causes cervical cancer has already reduced the virus’s prevalence in teenage girls by almost two-thirds, federal researchers said Monday.
Gardasil 9 Indication Now Covers More Male Patients
Thursday, December 17, 2015
Merck announced that the Food and Drug Administration (FDA) has expanded the age indication for Gardasil 9 (human papillomavirus 9-valent vaccine [recombinant]) in males. It now includes use in males aged 16–26 for the prevention of anal cancer caused by human papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 59; precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58; and genital warts caused by HPV types 6 and 11.
PAS: Communication style influences HPV vaccination
Tuesday, June 2, 2015
More adolescents received the HPV vaccine when the vaccine was discussed in the context of other vaccines, and when the providers said they expected that the vaccine would be administered at the visit, results from a multisite study suggest.
Practice- and Community-Based Interventions to Increase Human Papillomavirus Vaccine Coverage
Tuesday, June 2, 2015
Vaccines against human papillomavirus (HPV) are recommended for routine use in adolescents aged 11 to 12 years in the United States, but uptake remains suboptimal. Educational interventions focused on parents and patients to increase coverage have not generally demonstrated effectiveness.
Missed Opportunities for HPV Vaccination in Adolescent Girls: A Qualitative Study
Saturday, September 6, 2014
The goal of this study was to identify the rationale by parents/guardians and providers for delaying or administering human papillomavirus (HPV) vaccination to girls.
HPV vaccine safe for teens, provides long-term benefits
Wednesday, August 27, 2014
"When administered to adolescents, the HPV4 vaccine demonstrated durability in clinically effective protection and sustained antibody titers over eight years," concluded the researchers.
Scandinavia study finds HPV vaccine safe
Sunday, October 13, 2013
A new study from the Karolinska Institutet in Sweden found no association between the human papillomavirus (HPV) vaccine and short- or long-term health concerns.